as 05-20-2024 2:33pm EST
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Founded: | 1984 | Country: | India |
Employees: | N/A | City: | N/A |
Market Cap: | 11.5B | IPO Year: | N/A |
Target Price: | $81.00 | AVG Volume (30 days): | 199.9K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | 1.40% | Dividend Payout Frequency: | Annual |
EPS: | 3.25 | EPS Growth: | 91.16 |
52 Week Low/High: | $53.13 - $77.72 | Next Earning Date: | 05-07-2024 |
Revenue: | $2,991,228,710 | Revenue Growth: | 14.69% |
Revenue Growth (this year): | 14.45% | Revenue Growth (next year): | 6.75% |
RDY Breaking Stock News: Dive into RDY Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Morningstar Research
12 days ago
Insider Monkey
12 days ago
Morningstar Research
12 days ago
Zacks
12 days ago
Business Wire
13 days ago
Business Wire
17 days ago
GlobeNewswire
2 months ago